Thursday, July 27, 2023
Reece Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) has made an exciting announcement regarding the progress of its Phase I/II clinical trial for a new class of synthetic anti-infectives targeting urinary tract infections (UTIs). Both male and female subjects have been successfully dosed in the trial, which is being conducted at Scientia Clinical Research in Sydney, New South Wales.
To expedite patient recruitment and expand the trial's reach, Reece Pharmaceuticals added Scientia Clinical Research as a trial site, a decision that has proven fruitful. Dosing at the site has progressed ahead of schedule, with subjects receiving R327 through intravenous administration at faster infusion rates of 2,500mg.
The trial is proceeding well and is on track to meet its primary endpoints. The remaining subjects are set to be dosed at Scientia Clinical Research this week, with data read-outs expected in the second half of 2023. This milestone marks a significant advancement in the development of R327 as a potential treatment for urinary tract infections.
